{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:14:30Z","timestamp":1789352070998,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.hoc.2017.06.011","type":"journal-article","created":{"date-parts":[[2017,9,9]],"date-time":"2017-09-09T01:40:54Z","timestamp":1504921254000},"page":"853-868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Gene Therapy for Hemophilia"],"prefix":"10.1016","volume":"31","author":[{"given":"Amit C.","family":"Nathwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Davidoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward G.D.","family":"Tuddenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2017.06.011_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0950-3536(11)80025-9","article-title":"Epidemiology of coagulation disorders","volume":"5","author":"Nathwani","year":"1992","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.hoc.2017.06.011_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2516.2008.01837.x","article-title":"Clinical outcome of moderate haemophilia compared with severe and mild haemophilia","volume":"15","author":"den Uijl","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.hoc.2017.06.011_bib3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1046\/j.1365-2141.1996.d01-1679.x","article-title":"Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture","volume":"93","author":"Saldanha","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2017.06.011_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1423-0410.1996.7120126.x","article-title":"Hepatitis A transmission by factor IX concentrates","volume":"71","author":"Lawlor","year":"1996","journal-title":"Vox Sang"},{"key":"10.1016\/j.hoc.2017.06.011_bib5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0140-6736(05)78593-7","article-title":"New-variant Creutzfeldt-Jakob disease and treatment of haemophilia","volume":"351","author":"Baxter","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2017.06.011_bib6","first-page":"S33","article-title":"The hope and reality of long-acting hemophilia products","volume":"87","author":"Pipe","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2017.06.011_bib7","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2017.06.011_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2017.06.011_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V92.1.168.413k06_168_174","article-title":"Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice","volume":"92","author":"Kundu","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2017.06.011_bib11","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.94.21.11563","article-title":"A\u00a0factor IX-deficient mouse model for hemophilia B gene therapy","volume":"94","author":"Wang","year":"1997","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2017.06.011_bib12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V63.2.451.451","article-title":"Development of factor VIII: C antibodies in dogs with hemophilia A","volume":"63","author":"Giles","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib13","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1073\/pnas.86.24.10095","article-title":"Canine hemophilia B resulting from a point mutation with unusual consequences","volume":"86","author":"Evans","year":"1989","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2017.06.011_bib14","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","article-title":"Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A","volume":"344","author":"Roth","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2017.06.011_bib15","first-page":"116a","article-title":"Implantation of non-viral ex\u00a0vivo genetically modified autologous dermal fibroblasts that express B-domain deleted human factor VIII in 12 severe hemophilia A study subjects","volume":"100","author":"Roth","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib16","first-page":"832","article-title":"Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients","volume":"109","author":"Qiu","year":"1996","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.hoc.2017.06.011_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2002.1.1","article-title":"Ham-Wasserman lecture: hemophilia and related bleeding disorders: a story of dismay and success","volume":"2002","author":"Mannucci","year":"2002","journal-title":"Hematology"},{"key":"10.1016\/j.hoc.2017.06.011_bib18","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2017.06.011_bib20","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib21","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood-2006-03-010181","article-title":"Safe and efficient transduction of the liver after peripheral vein infusion of self complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates","volume":"109","author":"Nathwani","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib22","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1128\/JVI.78.6.3110-3122.2004","article-title":"Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors","volume":"78","author":"Thomas","year":"2004","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.hoc.2017.06.011_bib23","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2017.06.011_bib24","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2017.06.011_bib25","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2017.06.011_bib26","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","article-title":"Bioengineering of coagulation factor VIII for improved secretion","volume":"103","author":"Miao","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib27","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V81.11.2925.2925","article-title":"Biochemical, immunological, and in\u00a0vivo functional characterization of B-domain-deleted factor VIII","volume":"81","author":"Pittman","year":"1993","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2017.06.011_bib28","first-page":"S3","article-title":"Biosynthesis, assembly and secretion of coagulation factor VIII","volume":"8","author":"Kaufman","year":"1997","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.hoc.2017.06.011_bib29","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","volume":"103","author":"Miao","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib30","doi-asserted-by":"crossref","first-page":"18525","DOI":"10.1073\/pnas.0809677105","article-title":"Antioxidants reduce endoplasmic reticulum stress and improve protein secretion","volume":"105","author":"Malhotra","year":"2008","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2017.06.011_bib31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1055\/s-0037-1613369","article-title":"Molecular evolution of the vertebrate blood coagulation network","volume":"89","author":"Davidson","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2017.06.011_bib32","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1073\/pnas.96.22.12725","article-title":"Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein","volume":"96","author":"Burton","year":"1999","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2017.06.011_bib33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ymthe.2006.05.004","article-title":"Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B","volume":"14","author":"Jiang","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2017.06.011_bib34","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood.V95.5.1594.005k34_1594_1599","article-title":"Sustained expression of human factor VIII in mice using a parvovirus-based vector","volume":"95","author":"Chao","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib35","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1006\/mthe.2002.0607","article-title":"Expression of human factor VIII by splicing between dimerized AAV vectors","volume":"5","author":"Chao","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2017.06.011_bib36","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1038\/sj.mt.6300268","article-title":"The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene","volume":"15","author":"Chen","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2017.06.011_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/mt.2008.292","article-title":"Enhanced factor VIII heavy chain for gene therapy of hemophilia A","volume":"17","author":"Chen","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2017.06.011_bib38","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high-level expression","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.gt.3303080","article-title":"Analysis of factor VIII mediated suppression of lentiviral vector titres","volume":"15","author":"Radcliffe","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.hoc.2017.06.011_bib40","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib41","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2004.05058.x","article-title":"Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII","volume":"126","author":"Gringeri","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2017.06.011_bib42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2516.2003.00708.x","article-title":"The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A","volume":"9","author":"Lusher","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.hoc.2017.06.011_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2516.2006.01416.x","article-title":"Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria","volume":"13","author":"Pollmann","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.hoc.2017.06.011_bib44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1160\/TH06-09-0510","article-title":"Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice","volume":"98","author":"Lavigne-Lissalde","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2017.06.011_bib45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2017.06.011_bib46","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1006\/mthe.2001.0491","article-title":"Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males","volume":"4","author":"Arruda","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2017.06.011_bib47","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/mt.2012.47","article-title":"Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver","volume":"20","author":"Nowrouzi","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2017.06.011_bib48","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.06.011_bib49","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2017.06.011_bib50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-12-386509-0.00012-0","article-title":"Adeno-associated virus vectorology, manufacturing, and clinical applications","volume":"507","author":"Grieger","year":"2012","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.hoc.2017.06.011_bib51","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/gt.2008.61","article-title":"Toward exascale production of recombinant adeno-associated virus for gene transfer applications","volume":"15","author":"Cecchini","year":"2008","journal-title":"Gene Ther"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817301041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817301041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:05:10Z","timestamp":1760184310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858817301041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0889858817301041"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2017.06.011","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Therapy for Hemophilia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2017.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}